New Survey Finds People Living With HIV With Diarrhea Often Suffer in Silence
A change in the way doctors and patients talk about symptoms could better address this neglected comorbidity in HIV
The survey shows diarrhea remains prevalent in those living with HIV/AIDS, as 27 percent of respondents living with HIV/AIDS reported that they currently have diarrhea, while 56 percent reported that they have had diarrhea in the past. In addition, 79 percent of those with diarrhea reported having diarrhea for more than a year, and 61 percent reported having diarrhea for more than five years. Interestingly, while 72 percent said their doctor asked them about symptoms in general, only 31 percent said their doctor asked about diarrhea without them bringing it up first.
Highlights of the survey include:
- Long-term HIV survivors (individuals who have lived with HIV for 10+ years) have a higher prevalence of diarrhea, with 32 percent reporting they currently have diarrhea. In addition, 61 percent of long-term survivors reported suffering with diarrhea for at least five years.
- Of people living with HIV (PLWH) who have had diarrhea, less than half said their doctor asked them specifically about diarrhea.
- 30 percent of those currently experiencing diarrhea said they never discussed diarrhea with their doctor and/or reported feeling that the doctor dismissed or “blew off” their issue with diarrhea. Of all survey respondents, 19 percent who have ever experienced diarrhea said they never discussed diarrhea with their doctor.
Only one percent of survey respondents who currently have diarrhea
reported being told by their doctor about Mytesi®
(crofelemer), the only drug that has been specifically studied in and
FDA-approved for symptoms of diarrhea in people living with HIV.
“These results demonstrate that chronic diarrhea continues to be a
substantial complaint of HIV/AIDS patients, and particularly in the
growing group of long-term survivors,” stated
To view the full report of the survey results click here: http://www.enoughdiarrhea.com/surveyreport/SymptomSurveyReportNov2017.pdf
Launched by Napo in
To learn more about what you can do about HIV/AIDS-related diarrhea, visit www.mytesi.com.
Napo sponsored the nationwide survey of 350 people living with HIV/AIDS
and developed it with input from HIV advocates
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the